NSE: ALKEM | BSE: 539523

Strong Performer, Getting Expensive

Download real time

5668.50 25.00 (0.44%)

Near 52W High of ₹5786.90

228.9K NSE+BSE Volume

NSE 07 Nov, 2025 3:31 PM (IST)

67,775.4

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Board Meeting

The next board meeting for Alkem Laboratories Ltd. is on 13 Nov 2025 for the purpose of Quarterly Results See details

Alkem Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ALKEM, BSE:539523 Alkem Laboratories Ltd.

Search Inside the pdf :

Alkem Laboratories Ltd.

19 Sep 2025

5668.50

0.44%

CXO 1x1: Dr. Vikas Gupta, CEO

Buy: Alkem Laboratories Ltd.

Target

ICICI Securities Limited

Alkem Laboratories’ CEO, Dr. Vikas Gupta, is targeting double-digit revenue growth in the medium term, driven by strong hold in India (68% of sales), other international markets and new ventures.

Number of FII/FPI investors increased from 551 to 589 in Sep 2025 qtr.

Alkem Laboratories Ltd.

13 Aug 2025

5668.50

0.44%

Strong show; growth outlook improving

Buy: Alkem Laboratories Ltd.

Recommendation Target

ICICI Securities Limited

Alkem Laboratories (Alkem)’s Q1FY26 performance exceeded our expectations on all fronts. The outperformance was led by a strong showing in India (up 12%) and improved momentum across US (+8.8%) and other international markets (+9%).

Alkem Laboratories L.. has an average target of 5463.50 from 2 brokers.

Alkem Laboratories Ltd.

30 May 2025

5668.50

0.44%

Alkem Labs (SELL): FY26 to be as flat as FY25

Sell: Alkem Laboratories Ltd.

BOB Capital Markets Ltd.

Alkem missed our estimates where Sales /EBITDA /PAT were 0.4%/17% and 15%. EBITDA margin was 160 bps lower than estimates

Number of FII/FPI investors increased from 551 to 589 in Sep 2025 qtr.

Alkem Laboratories Ltd.

08 Feb 2025, 12:00AM

5668.50

0.44%

Alkem Labs (SELL): Slower growth in a seasonally strong quarter

Sell: Alkem Laboratories Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Domestic sales were 6% below our estimates mainly due to slower recovery in the acute therapies and no price hike in NLEM portfolio

Alkem Laboratories L.. has an average target of 5463.50 from 2 brokers.

Alkem Laboratories Ltd.

14 Nov 2024

5668.50

0.44%

Alkem Labs (BUY): In-line Q2, margins expected to sustain due to cost efficiencies

Buy: Alkem Laboratories Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Q2 reported in-line numbers, where sales/EBITDA were 4% below our estimates. However, PAT was 1% above our estimate

Alkem Laboratories L.. has an average target of 5463.50 from 2 brokers.

Alkem Laboratories Ltd.

03 Sep 2024

5668.50

0.44%

Focusing on profitable growth across segments

Neutral: Alkem Laboratories Ltd.

Target

Motilal Oswal

With an established presence in the Domestic Formulation (DF) segment and exports, ALKEM is boosting its growth prospects in the bio-CDMO and med-tech segments. The overall investment in the bio-CDMO segment is expected to be ~INR14b.

Number of FII/FPI investors increased from 551 to 589 in Sep 2025 qtr.

Alkem Laboratories Ltd.

10 Feb 2024

5668.50

0.44%

Alkem Labs (SELL): Good quarter; cut to SELL on stretched valuations

Sell: Alkem Laboratories Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Revenue grew 9% YoY in Q3 backed by strong India and ROW growth that offset lower US business

Number of FII/FPI investors increased from 551 to 589 in Sep 2025 qtr.

Alkem Laboratories Ltd.

08 Nov 2023, 12:00AM

5668.50

0.44%

Alkem Labs (HOLD): Sizeable margin gains; tax guided to reduce raise to HOLD

Hold: Alkem Laboratories Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Q2 EBITDA/PAT outstripped consensus by 44%/54% on higher margins, strong US growth and low taxes

Alkem Laboratories Ltd. is trading above all available SMAs

Alkem Laboratories Ltd.

11 Aug 2023

5668.50

0.44%

India muted, US drives show

Sell: Alkem Laboratories Ltd.

Recommendation Target

ICICI Securities Limited

On a low base, Alkem’s Q1FY24 revenue / EBITDA / PAT grew 15% / 91% / 125% YoY, marginally ahead of our expectations. Growth in India was dragged by its trade generics biz (17-18% of India sales) though branded biz did better. Management has lowered its India revenue growth guidance to single digits owing to lacklustre outlook.